Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us


A Cancer Drug Nears the Home Stretch

Dendreon (DNDN), which develops vaccines that boost a patient's immunity against cancer, could soon get a big lift from the Food & Drug Administration. The FDA is expected to announce that Dendreon may speed up its Phase 3 clinical trials on Provenge, a therapeutic vaccine for hormone-resistant prostate cancer. That would expedite Dendreon's application for final approval of Provenge.

Prostate cancer is the most common cancer among American men, says Mark Monane of investment firm Needham, who rates the stock a buy. Trading at 11 last year, the stock is now at 4, reflecting the biotech slump. Results of Provenge's first Phase 3 trial showed good results, says Mitchell Gold, who takes over as CEO on Jan. 1, 2003. The second Phase 3 trials now under way--with only advanced-prostate-cancer patients enrolled--will provide pivotal evidence needed to seek FDA approval. Overall, Provenge was well tolerated, says Gold, with the most common side effects being chills and fever, which were most often infusion-related. Needham's Monane expects the company to be in the black by 2004, when he forecasts earnings of 88 cents a share. By Gene Marcial

blog comments powered by Disqus